PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events

Neurology. 2004 Oct 12;63(7):1217-22. doi: 10.1212/01.wnl.0000140493.83607.f1.

Abstract

Objective: To assess the impact of the Preventing Recurrence of Thromboembolic Events through Coordinated Treatment (PROTECT) Program on achievement of its eight secondary prevention goals at the time of discharge.

Methods: Achievement rates for the eight program goals at time of discharge were compared in all patients discharged from a university hospital-based stroke service with a diagnosis of ischemic stroke or TIA during a 1-year period after implementation of the PROTECT Program vs rates obtained from a comparable group of patients admitted to the same service during the preceding year.

Results: Demographic and medical features were comparable in the baseline and intervention cohorts for all patients with cerebral ischemia presumed due to large-vessel atherosclerosis or small-vessel disease (baseline year n = 117, intervention n = 130). Implementation rates in patients without specific contraindications increased for all four medication goals: 97 to 100% for antithrombotic agents, 68 to 97% for statins, 42 to 90% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 14 to 70% for diuretics. Although data were not collected on baseline lifestyle instruction rates, instruction in the program's four lifestyle interventions was achieved by discharge in 100% of the intervention cohort.

Conclusion: Implementation of this single-center, systems-based, in-hospital program to initiate secondary stroke prevention therapies was associated with a substantial increase in treatment utilization at the time of hospital discharge.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antihypertensive Agents / therapeutic use
  • Behavior Therapy
  • Brain Ischemia / therapy
  • Cerebrovascular Disorders / prevention & control*
  • Combined Modality Therapy
  • Feasibility Studies
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Health Behavior
  • Hospitals, Teaching
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Intracranial Arteriosclerosis / therapy
  • Male
  • Middle Aged
  • Patient Education as Topic
  • Pilot Projects
  • Recurrence
  • Stroke / therapy*
  • Thromboembolism / prevention & control*

Substances

  • Antihypertensive Agents
  • Fibrinolytic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors